M
Michaela Lehle
Researcher at Hoffmann-La Roche
Publications - 32
Citations - 7722
Michaela Lehle is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Emicizumab & Trastuzumab. The author has an hindex of 14, co-authored 25 publications receiving 6440 citations.
Papers
More filters
Journal ArticleDOI
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang,Eric Van Cutsem,A. Feyereislova,Hyun Cheol Chung,Lin Shen,Akira Sawaki,Florian Lordick,Atsushi Ohtsu,Yasushi Omuro,Taroh Satoh,G. Aprile,Evgeny Kulikov,Julie Hill,Michaela Lehle,Josef Rüschoff,Yoon-Koo Kang +15 more
TL;DR: Trastuzumab in combination with chemotherapy can be considered as a new standard option for patients with HER2-positive advanced gastric or gastro-oesophageal junction cancer.
Journal ArticleDOI
Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.
Bella Kaufman,John R. Mackey,Michael R. Clemens,P.P. Bapsy,Ashok K. Vaid,Andrew M Wardley,Sergei Tjulandin,Michaela Jahn,Michaela Lehle,A. Feyereislova,Cedric Revil,Alison Jones +11 more
TL;DR: Trastuzumab plus anastrozole improves outcomes for patients with HER2/hormone receptor-copositive MBC compared with anast rozole alone, although adverse events and serious adverse events were more frequent with the combination.
Journal ArticleDOI
HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
Eric Van Cutsem,Yung-Jue Bang,Feng Feng-yi,Jian M. Xu,Keun-Wook Lee,Shun-Chang Jiao,Jorge León Chong,Roberto I. López-Sanchez,Timothy J. Price,Oleg Gladkov,Oliver Stoss,Julie Hill,Vivian Ng,Michaela Lehle,Marlene Thomas,Astrid Kiermaier,Josef Rüschoff +16 more
TL;DR: All patients with advanced gastric or gastroesophageal junction cancer should be tested for HER2 status, preferably using IHC initially, and due to the unique characteristics of gastric cancer, specific testing/scoring guidelines should be adhered to.
Journal ArticleDOI
Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC)
E. Van Cutsem,Y-K Kang,H.C. Chung,Liang Shen,Akira Sawaki,Florian Lordick,Julie Hill,Michaela Lehle,A. Feyereislova,Y.-J. Bang +9 more
TL;DR: This first randomized trial investigating anti-HER2 therapy in advanced GC showed that H+CT is superior to CT alone, indicating that H is a new, effective, and well-tolerated treatment for HER2-positive GC.
Journal ArticleDOI
Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study
Steven W. Pipe,Midori Shima,Michaela Lehle,Amy D. Shapiro,Sammy Chebon,Katsuyuki Fukutake,Nigel S. Key,Agnès Portron,Christophe Schmitt,Maria Podolak-Dawidziak,Nives Selak Bienz,Cédric Hermans,Avrita Campinha-Bacote,Anna Kiialainen,Kathelijne Peerlinck,Gallia G. Levy,Víctor Jiménez-Yuste +16 more
TL;DR: Emicizumab given once every 4 weeks showed clinically meaningful bleed control while being well tolerated, and could improve patient care by decreasing treatment burden and increasing adherence to effective prophylaxis, potentially decreasing the development of secondary complications for people with haemophilia A.